Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) (GGB or the Company) today announced an agreement (the Agreement) with DSW Inc. (NYSE: DSW) (DSW) to sell hemp-derived cannabidiol (CBD) personal care products under the Seventh Sense Botanical Therapy brand at select DSW stores throughout the U.S. Also today, CannabisNewsWire released an Audio Press Release (APR) titled “US President, Producers Envision ‘Green Acres’ with Signing of Historic Hemp-Legalizing Farm Bill,” featuring Green Growth Brands (CSE: GGB) (OTCQB: GGBXF). To hear the CannabisNewsAudio version, visit: http://cnw.fm/DkqS7. To read the full editorial, visit: http://cnw.fm/9xsqL. Additionally, the company was highlighted in an article examining how the end of the year was a large turning point for the marijuana industry, as the year's events were instrumental in cementing the growth of the cannabis sector around the world.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

• CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
• Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
• Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
• Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
• The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
• XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $4.2043, up 3.85%, on 1,200 volume with 466 trades. The average volume for the last 3 months is 2,975 and the stock's 52-week low/high is $1.8068/$4.369.

Recent News

• Green Growth Brands Partners with DSW to Sell Seventh Sense CBD Products
• CannabisNewsAudio Announces Audio Press Release (APR) on Green Growth Brands Leveraging Key Strategies to Dominate CBD Products Market
• Xanthic Biopharma Inc. (d.b.a. Green Growth Brands) Announces Name Change to Green Growth Brands Inc.

The Flowr Corporation (TSX.V: FLWR)

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation (FLWR).

The Flowr Corporation’s (TSX.V: FLWR) (OTC: FLWPF) acquisition of 19.8 percent of Holigen Limited for a cash payment of C$6 million and the signing of an intellectual property sharing agreement is expected to have far-reaching benefits for the company. Flowr says that it will result in an acceleration of Holigen’s projects, including an outdoor cultivation license on a seven million square foot site in Portugal with the potential to produce 500,000 kg of cannabis products annually (http://cnw.fm/o4GEc).

The Flowr Corporation (TSX.V: FLWR), a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

• FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
• Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
• Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

The Flowr Corporation (TSX.V: FLWR), closed the day's trading session at $4.60, up 1.10%, on 97,756 volume with 217 trades. The average volume for the last 3 months is 92,038 and the stock's 52-week low/high is $2.74/$8.00.

Recent News

• The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) Identifies Acquisition of Stake in Holigen as ‘Transformative Transaction’
• Flowr Signs Medical Cannabis Supply Agreement With Shoppers Drug Mart
• The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) Identifies Acquisition of Stake in Holigen as ‘Transformative Transaction’

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE), a client of NNW currently focused on the development of cobalt projects within Indonesia. To view the full publication, titled “Global EV Demand Drives Scramble for Fresh Supplies of Vital Metals,” visit: http://nnw.fm/2liAM.

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated (http://nnw.fm/u1HNs). “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed the day's trading session at $0.124375, up 8.15%, on 31,750 volume with 9 trades. The average volume for the last 3 months is 17,197 and the stock's 52-week low/high is $0.0701/$1.117.

Recent News

• NetworkNewsWire Announces Publication on Multinational Companies and Industrialized Nations Working to Secure Critical Metals
• Global EV Demand Drives Scramble for Fresh Supplies of Vital Metals
• Pacific Rim Cobalt Provides Update to Shareholders on 2018 Progress

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (MCOA), an innovative hemp and cannabis corporation, and its Joint Venture partner Global Hemp Group Inc. (CSE: GHG/ OTC: GBHPF/ FRA: GHG) are pleased to announce that clone production for the 2019 season at their Scio, Oregon High Yielding CBD Hemp project is now in high gear, in preparation for an “as early as possible” planting this year. Also today, the company was highlighted in a report examining how Cannabis/Hemp/CBD companies are always looking to identify crops that can bring best yield from the crops they grow. The hottest commodity today is growing hemp for CBD extraction.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.019, up 11.11%, on 11,605,040 volume with 581 trades. The average volume for the last 3 months is 14,130,441 and the stock's 52-week low/high is $0.0115/$0.0577.

Recent News

• Clone Production at Marijuana Company of America’s Scio Oregon Hemp Project Underway – Hemp Growers License Renewed for 2019
• Advanced Studies and Latest Innovation Helping Hemp/CBD Companies Increase Yields
• 420 with CNW – CARERS Act Seeks to Reform Federal Marijuana Law

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout (OTC: GOHE) together with its wholly-owned subsidiary MTrac Tech Corp. this morning announced the release of its system’s API for the purpose of integration with some of the cannabis industry’s leading point of sale (“POS”) companies. To view the full press release, visit: http://nnw.fm/TcP1w.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.0067, even for the day, on 6,591,659 volume with 104 trades. The average volume for the last 3 months is 9,177,678 and the stock's 52-week low/high is $0.0041/$0.0575.

Recent News

• NetworkNewsBreaks – Global Payout, Inc. (GOHE) and MTrac Begin POS Integrations to Drive Paradigm Shifts, Mass Market Adoption
• NetworkNewsBreaks – Global Payout, Inc. (GOHE) and MTrac Provide Shareholder Update, Look Back at Accomplishments and Forward to Extraordinary 2019
• NetworkNewsBreaks – Global Payout, Inc. (GOHE) Executes Licensing Agreement with GreenBox POS (GRBX)

Cyberfort Software, Inc. (CYBF)

The QualityStocks Daily Newsletter would like to spotlight Cyberfort Software, Inc. (OTC: CYBF).

Driven by algorithms that analyze our online histories, the advent of digital advertising has raised the level of intrusiveness to such unbearable levels that a recent survey found that two-thirds of respondents “are fed up with online advertising” and are prepared to “walk away from brands that deliver it.” Cyberfort Software, Inc. (OTC: CYBF) has tools to help them do exactly that. With content filtering and ad-blocking, the tech outfit is developing solutions to strengthen the cyber security of companies and consumers.

Cyberfort Software, Inc. (CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Committed to the idea that everyone – from individuals to global corporations – should be able to enjoy a digital future free of malicious attacks robbing them of privacy and security, Cyberfort is working to strengthen its portfolio of cybersecurity IPs and stay one step ahead of cyberthreats. The growing plethora of tech devices enveloping everyday life opens the door to increasing cyberattacks through a stunning array of sophisticated cyberthreats. Protecting organizations and individuals with proactive security postures and protective measures is a key component of Cyberfort’s strategy to develop cybersecurity solutions that are smart, simple and efficient.

The company’s 2016 purchase of Vivio, a provider of pioneering AI content filtering and software protection, underscores Cyberfort’s commitment to cybersecurity. Vivio, an iOS 10 ad blocking app, currently serves over 10,000 unique users across iPhone, iPad and Mac. Vivio makes web browsing better, faster and more satisfying by blocking ads and reducing data usage, which also helps save battery life. Continuous ad blocking rule updates are delivered via an Intellectual Property Cloud-based autonomous engine with ad blocking tracker and malware detection filters.

Cyberfort recently signed a letter of intent to acquire Just Content Software which includes the Just Content app, software and underlying source code. Just Content is an efficacious and multi-functional ad blocking app that safeguards families and businesses with proprietary “Home Safe Filter” and “Business Filter” products. The Just Content app is available on iTunes and protects against unsafe links, adult content, phishing sites and inflammatory hate speech found on the internet, among other potential backdoor attacks and cyberthreats. A due diligence review is underway and a final determination regarding this acquisition is anticipated within weeks.

“Cyberfort aims to become a leader in developing cutting edge ad-blocking protective software that keeps the internet safe for families and business, which in our highly technological and immediate information-access society is a significant concern. Acquiring Just Content furthers our commitment to provide the best and most effective ad-blocking software in the marketplace,” says Cyberfort CEO Daniel Cattlin.

Favorable government regulations promoting tightened web security is a major factor driving adoption of web content filtering solution along with the public’s growing desire to better manage network bandwidth consumption and protect their online security and privacy. Cyberfort’s objective is to protect the data and integrity of personal and business computing assets and defend those assets against any threat or attack. The company’s software also offers symbiotic ad-blocking capabilities to complement its cyber defense effectiveness.

As Cyberfort continues to innovate, the Vivio team intends to leverage the current user base as a sandbox to test and optimize future incremental developments targeting an enterprise suite of tools that can be integrated into sector specific areas of growth. Key areas of focus include mobile device management, bring your own device (“BYOD”), mobile app management and secure mobile browser.

The Cyberfort leadership team is headlined by Cattlin, who offers a new age perspective to the business with expertise in project and asset management and a background in corporate finance. Cattlin brings both the operational and financial understanding to take companies from start-up and early development to expansion and capital growth within a public environment.

Chief Technology Officer Tomas Mistrik helped his team deliver a variety of technological products including the Vivio ad-blocking app for iOS 10 and the Silicon Valley-based Synergykit platform for mobile developers.

Technology Development Manager Krishna Kumar brings more than 10 years of experience in the Information Technology industry where he provided powerful security and ad-blocking measures for companies such as CSC and PayPal India.

Senior Advisor Harish Doddala brings nine years of product management and software engineering experience, delivering results for Cisco, VMware, Oracle, IBM and Siemens.

Cyberfort Software, Inc. (OTC: CYBF), closed the day's trading session at $0.22, off by 14.56%, on 2,500 volume with 1 trade. The average volume for the last 3 months is 15,638 and the stock's 52-week low/high is $0.051/$69.00.

Recent News

• Cyberfort Software, Inc. (CYBF) Offers Tech Armory to Fight Off Ad Attack
• NetworkNewsBreaks – Cyberfort Software, Inc. (CYBF) Aiming for Success in the $153B Global Cyber Security Market
• NetworkNewsBreaks – Cyberfort Software, Inc.’s (CYBF) Vivio App Fends Off Potential Cyber Security Threats

Plus Products Inc. (CSE: PLUS) (OTC: PLSPF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLSPF).

Plus Products Inc. (CSE: PLUS) was featured today in a report by CannabisNewsWire examining how the Department of Health in Rhode Island has scheduled a public hearing early next month to collect views about a petition that calls for cannabis to be used to help people wean off prescription opioids.

Plus Products Inc. (CSE: PLUS) (OTC: PLSPF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

• Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
• Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
• Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
• Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
• Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
• Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLUS), closed the day's trading session at $3.4899, off by 1.42%, on 62,890 volume with 34 trades. The average volume for the last 3 months is 105,683 and the stock's 52-week low/high is $2.81/$4.25.

Recent News

• 420 with CNW – Rhode Island Considers Using Medical Cannabis to Stop Opioid Dependency
• Plus Products Inc. (CSE: PLUS) Solidifies Leading Edibles Position in California with Acquisition of Cannabis-Infused Baked Goods Manufacturer
• Benzinga Cannabis Capital Conference Will Bring Cannabis Visionaries and Investors Together

Zenergy Brands, Inc. (ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

Energy consumers’ ability to efficiently manage their usage is beginning to acquire the same importance as other environmental impact and pollution reduction concerns, and next-generation energy utility companies such as Zenergy Brands, Inc. (OTC: ZNGY) are working to make a better world possible. For years, the science community has expressed interest in evidence of changes to the earth’s climate on a significant scale.

Zenergy Brands, Inc. (ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.0002, up 100.00%, on 276,019,687 volume with 72 trades. The average volume for the last 3 months is 64,170,646 and the stock's 52-week low/high is $0.000009/$0.013.

Recent News

• Zenergy Brands, Inc. (ZNGY) Builds Consumers’ Capacity to Efficiently Manage Utilities Use While Conserving the Environment
• Zenergy Brands, Inc. (ZNGY) Offers Customers the Ability to Retrofit Outdated Energy Options with Intuitive Products and Services
• NetworkNewsBreaks – Zenergy Brands, Inc. (ZNGY) Utilizing REP Division to Promote its Zero Cost Program

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4)

The QualityStocks Daily Newsletter would like to spotlight Redfund Capital Corp. (PNNRF).

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (Frankfurt: O3X4) was featured today in a report by CannabisNewsWire examining how the Department of Health in Rhode Island has scheduled a public hearing early next month to collect views about a petition that calls for cannabis to be used to help people wean off prescription opioids.

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4) is a merchant bank focused on providing debt and equity funding in the mid to late stages of a target company’s development and for technologies that are developed and validated by revenues. Redfund’s current focus is on medical cannabis, hemp and cannabidiol (CBD) related and healthcare-related companies.

As the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility, Redfund is effectively bridging finance gaps and helping revenue-producing medical cannabis-related companies grow and build their valuations without prematurely diluting their equity.

The central components of the company’s business strategy are:

• Establishing the foundation of a loan portfolio that generates revenues through monthly interest income from loans to cover all general and administrative expenses related to day-to-day operations.
• Growing shareholder value by converting all or part of loans and warrants into equity in portfolio clients as clients build their valuations by entering the public markets or becoming the high-priced targets of larger entities.

Redfund was designed by bankers and entrepreneurs possessing years of experience in business, consulting, capital markets, corporate finance and healthcare services. The company is actively looking beyond borders and creating global companies that have strong fundamentals and are ready to expand.

Redfund’s investments are deployed to companies that have demonstrated success in their business but need a capital bridge in order to expand. Redfund’s team of professionals vet every project and analyzes each prospective client’s financials and business plans. Once a project is approved, Redfund’s legal team carefully scrutinizes the collateral used to securitize the individual loans.

The strategy employed by Redfund includes:

• Diversifying investments in Canada and other countries
• Building an international footprint with established national leaders
• Funding new drug delivery systems and helping nutraceuticals become mainstream drugs
• Introducing companies to Canada as a viable option for public listings
• Becoming a premier go-to lender for established companies

The company’s revenue sources include:

• Interest-bearing debt instruments with asset-backed collateral to securitize loans
• Equity kicker of warrants coverage on original loan
• Conversion ability of loan in its entirety
• Advisory fees from contracts for consulting on growth strategies
• Right of first refusal on future financing in each company funded

Redfund Capital Corp. (PNNRF), closed the day's trading session at $0.10, even for the day, on 500 volume. The average volume for the last 3 months is 279 and the stock's 52-week low/high is $0.10/$0.51.

Recent News

• 420 with CNW – Rhode Island Considers Using Medical Cannabis to Stop Opioid Dependency
• NetworkNewsBreaks – Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) Focuses on Medical Cannabis, Hemp and CBD-related Companies as Export Laws Begin to Shift in Israel
• Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (Frankfurt: O3X4) Finishes 2018 on a Strong Note, New Developments Announced

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) (FRA: 53S1) works to identify new opportunities to build unique cannabis businesses. The company’s 7ACRES licensed producer subsidiary operates a 440,000 sq. ft. facility in Ontario, Canada. 7ACRES’ specialty is growing high-quality cannabis in large quantities. Supreme Cannabis Company has its corporate headquarters in Toronto, Ontario.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.30, off by 0.76%, on 337,394 volume with 437 trades. The average volume for the last 3 months is 518,201 and the stock's 52-week low/high is $0.85/$2.49.

Recent News

• The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) (FRA: 53S1) Inks Consulting Agreement with Khalifa Kush Enterprises
• Supreme Cannabis Receives Conditional Approval to List on the Toronto Stock Exchange
• The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) (FRA: 53S1) Set to Have All 25 7ACRES Flowering Rooms Completed by March 2019

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings (CSE: TCAN) announced the January 8, 2019 completion of its initial public offering (“IPO”) of 4,400,000 units, issued at a price of $0.50 per unit, which generated aggregate gross proceeds of $2,200,000 pursuant to a December 10, 2018 prospectus. The warrants are issued pursuant to an indenture dated January 8, 2019 between the company and its warrant agent, Odyssey Trust Company, with a copy available under the company's profile on SEDAR.com. To view the full press release, visit: http://nnw.fm/V68yr. Also today, the company was featured in a video by InvestmentPitch Media http://cnw.fm/N3JEd.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $0.91, off by 4.21%, on 63,200 volume with 24 trades. The stock's 52-week low/high is $0.47705/$1.02.

Recent News

• NetworkNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) Closes IPO Generating $2.2M in Gross Proceeds
• CSE New Listing - Transcanna Holdings Inc. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
• TransCanna Closes Initial Public Offering

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that David F. Welch, Ph.D., Founder, Chief Innovation Officer and Director of Infinera Corporation, has joined the CytoDyn Board of Directors.  Dr. Welch is an American businessman and research scientist who brings considerable strategic planning expertise and broad capital markets experience to the CytoDyn Board.  He is a significant investor in CytoDyn and understands leronlimab’s potential for targeting multiple disease processes.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.501, off by 12.11%, on 511,809 volume with 132 trades. The average volume for the last 3 months is 197,646 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

• CytoDyn Appoints David F. Welch, Ph.D. to Board of Directors
• CytoDyn to Deliver Presentation at Biotech Showcase Conference
• CytoDyn Names Richard G. Pestell, M.D., Ph.D. as Vice Chairman of its Board of Directors

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint (OTCQB:SING) a fully reporting technology company providing mobile payments, ancillary cannabis services and blockchain solutions prepares for 2019 and provides insight to company direction as well as acquisitions that the company will pursue. Additionally, the company provides insight to previous acquisitions it has completed and the successes of those to date.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

• A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
• A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
• A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
• Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
• Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
• Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.02, off by 8.68%, on 8,259,138 volume with 320 trades. The average volume for the last 3 months is 6,241,319 and the stock's 52-week low/high is $0.0106/$0.0995.

Recent News

• SinglePoint Looks Ahead to 2019 Highlighting Company Direction and Acquisitions
• CannabisNewsBreaks – SinglePoint, Inc. (SING) Invests in TorusMed Inc. for Lab-Based Development of CBD Cell Cultures
• SinglePoint Invests in TorusMed Inc. to Develop CBD Cell Cultures through Photobioreactors

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed the day's trading session at $0.0099, even for the day, on 18,000 volume. The average volume for the last 3 months is 400 and the stock's 52-week low/high is $0.0098/$0.0289.

Recent News

• Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) Sees Opportunity in Applying Novel Skin Remedies to Health Concerns
• NetworkNewsBreaks – Therma Bright, Inc.’s (TSX.V: THRM) (OTC: THRBF) Revolutionary Products Designed to Relieve Pain, Symptoms of Bites and Stings
• 420 with CNW – US States Hope Legal Marijuana Will Fix Pension Crisis